Stockreport

Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda [FOX Business Network]

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF A breakthrough personalized mRNA cancer vaccine that trains the immune system to target patients' unique tumor mutations is showing promising results. Five-year trial [Read more]